A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria.
CINE963A02103
Phase 1 other active
Quick answer
A study investigating the safety, tolerability, metabolism, and elimination of INE963, a new compound in the treatment of malaria. for Malaria is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Malaria
- Phase
- Phase 1
- Modality
- other
- Status
- active